Imidazole propionate from gut bacteria correlates with faster cognitive decline in 1,200 Wisconsin cohort participants

The team measured plasma ImP in participants from the Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center cohorts. Individuals in the highest ImP quartile showed steeper declines on composite cognitive scores and elevated CSF tau and amyloid ratios compared with lower-quartile peers, independent of age, APOE status, and BMI. A common genetic variant linked to reduced renal ImP clearance was present in 43% of the sample and previously associated with higher Alzheimer's risk in GWAS meta-analyses.

Prior work had already tied ImP to insulin resistance and coronary disease; the new data extend the metabolite's reach to the brain by demonstrating direct effects on beta-amyloid and tau accumulation in mouse models. Because ImP derives from bacterial metabolism of dietary histidine, the finding reframes the gut-brain axis as a modifiable metabolic rather than purely inflammatory pathway.

Dietary histidine restriction is unlikely to be feasible given its essential status, so therapeutic strategies will probably target either the producing bacteria or renal clearance. The observational design leaves open the possibility that reverse causation or unmeasured confounders explain the associations; randomized trials that lower ImP are now required.